995 related articles for article (PubMed ID: 15942051)
1. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.
Navarro JF; Milena FJ; Mora C; León C; Claverie F; Flores C; García J
Kidney Int Suppl; 2005 Dec; (99):S98-102. PubMed ID: 16336586
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of renal renin-angiotensin system in mouse diabetic nephropathy.
Tamura J; Konno A; Hashimoto Y; Kon Y
Jpn J Vet Res; 2005 Aug; 53(1-2):13-26. PubMed ID: 16190318
[TBL] [Abstract][Full Text] [Related]
5. Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes.
Zhang D; Yang H; Kong X; Wang K; Mao X; Yan X; Wang Y; Liu S; Zhang X; Li J; Chen L; Wu J; Wei M; Yang J; Guan Y
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E287-95. PubMed ID: 20959534
[TBL] [Abstract][Full Text] [Related]
6. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
Navarro JF; Milena FJ; Mora C; León C; García J
Am J Nephrol; 2006; 26(6):562-70. PubMed ID: 17167242
[TBL] [Abstract][Full Text] [Related]
7. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat.
Zimpelmann J; Kumar D; Levine DZ; Wehbi G; Imig JD; Navar LG; Burns KD
Kidney Int; 2000 Dec; 58(6):2320-30. PubMed ID: 11115066
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
9. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
10. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
12. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
Mima A; Arai H; Matsubara T; Abe H; Nagai K; Tamura Y; Torikoshi K; Araki M; Kanamori H; Takahashi T; Tominaga T; Matsuura M; Iehara N; Fukatsu A; Kita T; Doi T
Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
14. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
[TBL] [Abstract][Full Text] [Related]
15. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
[TBL] [Abstract][Full Text] [Related]
16. ACE and ACE2 activity in diabetic mice.
Wysocki J; Ye M; Soler MJ; Gurley SB; Xiao HD; Bernstein KE; Coffman TM; Chen S; Batlle D
Diabetes; 2006 Jul; 55(7):2132-9. PubMed ID: 16804085
[TBL] [Abstract][Full Text] [Related]
17. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli.
Xu ZG; Miao LN; Cui YC; Jia Y; Yuan H; Wu M
Nephrol Dial Transplant; 2009 Jun; 24(6):1744-52. PubMed ID: 19103735
[TBL] [Abstract][Full Text] [Related]
19. Identification of angiotensin converting enzyme 2 in the rodent retina.
Tikellis C; Johnston CI; Forbes JM; Burns WC; Thomas MC; Lew RA; Yarski M; Smith AI; Cooper ME
Curr Eye Res; 2004 Dec; 29(6):419-27. PubMed ID: 15764086
[TBL] [Abstract][Full Text] [Related]
20. Renal expression of proto-oncogene Ets-1 on matrix remodeling in experimental diabetic nephropathy.
Liu DX; Liu XM; Su Y; Zhang XJ
Acta Histochem; 2011 Sep; 113(5):527-33. PubMed ID: 20598359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
